Helene M Altmann1, Joseph Kazan1, Marie Anne Gebara1, Daniel M Blumberger2, Jordan F Karp3, Eric J Lenze4, Benoit H Mulsant2, Charles F Reynolds1, Sarah T Stahl5. 1. Department of Psychiatry (HMA, JK, MAG, CFR, STS), University of Pittsburgh, Pittsburgh, PA. 2. Centre for Addiction and Mental Health, Department of Psychiatry (DMB, BHM), University of Toronto, Toronto, ON, Canada. 3. Department of Psychiatry, College of Medicine (JFK), University of Arizona, Tucson, AZ. 4. Department of Psychiatry (EJL), Washington University, St. Louis, MO. 5. Department of Psychiatry (HMA, JK, MAG, CFR, STS), University of Pittsburgh, Pittsburgh, PA. Electronic address: Sarah.Stahl@pitt.edu.
Abstract
OBJECTIVE: Nonadherence to antidepressants interferes with optimal treatment of late-life depression. This analysis examines clinical and treatment factors predicting medication nonadherence in difficult-to-treat late-life depression. METHODS: Secondary analysis of data from a clinical trial of antidepressant pharmacotherapy for Major Depressive Disorder in 468 adults aged 60+ years. All participants received venlafaxine XR for 12 weeks. Nonremitters were randomized to augmentation with either aripiprazole or placebo for 12 additional weeks. Medication adherence was assessed 14 times over 24 weeks. The analyses examined sociodemographic, clinical, and treatment factors that may predict antidepressant nonadherence during early (weeks 1-6), late (weeks 7-12), and augmentation (weeks 13--24) treatment. RESULTS: Poor cognitive function and early response were predictive of early nonadherence. Poor cognitive function and prior nonadherence were predictive of late nonadherence. Living alone was associated with nonadherence both late and during augmentation treatment. CONCLUSION: Future studies should consider the role of early response and cognitive function to improve antidepressant adherence, particularly among older adults who live alone.
OBJECTIVE: Nonadherence to antidepressants interferes with optimal treatment of late-life depression. This analysis examines clinical and treatment factors predicting medication nonadherence in difficult-to-treat late-life depression. METHODS: Secondary analysis of data from a clinical trial of antidepressant pharmacotherapy for Major Depressive Disorder in 468 adults aged 60+ years. All participants received venlafaxine XR for 12 weeks. Nonremitters were randomized to augmentation with either aripiprazole or placebo for 12 additional weeks. Medication adherence was assessed 14 times over 24 weeks. The analyses examined sociodemographic, clinical, and treatment factors that may predict antidepressant nonadherence during early (weeks 1-6), late (weeks 7-12), and augmentation (weeks 13--24) treatment. RESULTS: Poor cognitive function and early response were predictive of early nonadherence. Poor cognitive function and prior nonadherence were predictive of late nonadherence. Living alone was associated with nonadherence both late and during augmentation treatment. CONCLUSION: Future studies should consider the role of early response and cognitive function to improve antidepressant adherence, particularly among older adults who live alone.
Authors: Floor Holvast; Richard C Oude Voshaar; Hans Wouters; Karin Hek; Francois Schellevis; Huibert Burger; Peter F M Verhaak Journal: Fam Pract Date: 2019-01-25 Impact factor: 2.267
Authors: M D Miller; C F Paradis; P R Houck; S Mazumdar; J A Stack; A H Rifai; B Mulsant; C F Reynolds Journal: Psychiatry Res Date: 1992-03 Impact factor: 3.222
Authors: Jo Anne Sirey; Samprit Banerjee; Patricia Marino; Martha L Bruce; Ashley Halkett; Molly Turnwald; Claire Chiang; Brian Liles; Amanda Artis; Fred Blow; Helen C Kales Journal: JAMA Psychiatry Date: 2017-11-01 Impact factor: 21.596
Authors: Alexandra Woods; Nili Solomonov; Brian Liles; Arielle Guillod; Helen C Kales; Jo Anne Sirey Journal: Am J Geriatr Psychiatry Date: 2021-01-05 Impact factor: 7.996
Authors: Meryl A Butters; Jeffrey B Young; Oscar Lopez; Howard J Aizenstein; Benoit H Mulsant; Charles F Reynolds; Steven T DeKosky; James T Becker Journal: Dialogues Clin Neurosci Date: 2008 Impact factor: 5.986
Authors: M N Sabbagh; M Boada; S Borson; M Chilukuri; B Dubois; J Ingram; A Iwata; A P Porsteinsson; K L Possin; G D Rabinovici; B Vellas; S Chao; A Vergallo; H Hampel Journal: J Prev Alzheimers Dis Date: 2020